Nov 11O0.9550H0.9600L0.8800C0.9001Vol15.37M
Allogene Therapeutics Inc stock is traded at $0.9001, with a volume of 15,369,384. It is down -3.41% in the last 24 hours and down -35.71% over the past month. Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Previous Close:
$0.9319
Open:
$0.955
24h Volume:
15,369,384
Relative Volume:
1.11
Market Cap:
$311.86M
Revenue:
$22,000
Net Income/Loss:
-$173.76M
P/E Ratio:
-
EPS:
-$0.7681
Net Cash Flow:
-$109.53M
1W Performance:
-17.42%
1M Performance:
-35.71%
6M Performance:
-60.87%
1Y Performance:
-26.82%
1-Day Range:
$0.88$0.96
1-Week Range:
$0.88$1.13
52-Week Range:
$0.88$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(650) 457-2700Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS